Merck (MRK) Long-Term Debt Issuances (2010 - 2025)
Merck (MRK) reported Long-Term Debt Issuances of $7.9 billion for Q4 2025, up 32.81% on a QoQ basis from $6.0 billion in Q3 2025.
Merck (MRK) has 11 years of Long-Term Debt Issuances data on file, last reported at $7.9 billion in Q4 2025.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $7.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.9 billion (up 173587.5% YoY) and the FY2025 annual result came in at $13.9 billion, up 285.66% from the prior year.
- Long-Term Debt Issuances rose to $7.9 billion in Q4 2025 per MRK's latest filing, from $6.0 billion in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $7.9 billion in Q4 2021 and bottomed at -$7.0 million in Q3 2023.
- The 4-year median for Long-Term Debt Issuances is $6.0 billion (2025), against an average of $4.4 billion.
- The widest annual swing landed in 2024, when Long-Term Debt Issuances soared 85.71%; it then jumped 596300.0% in 2025.
- Tracing MRK's Long-Term Debt Issuances over 4 years: stood at $7.9 billion in 2021, then plunged by 100.09% to -$7.0 million in 2023, then jumped by 85.71% to -$1.0 million in 2024, then jumped by 791900.0% to $7.9 billion in 2025.
- Per Business Quant, the three latest MRK Long-Term Debt Issuances figures stand at $7.9 billion (Q4 2025), $6.0 billion (Q3 2025), and -$1.0 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.92 Bn |
| Dec 31, 2025 | 7.92 Bn |
| Sep 30, 2025 | 5.96 Bn |
| Sep 30, 2025 | 5.96 Bn |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2023 | -7.00 Mn |
| Sep 30, 2023 | -7.00 Mn |
| Dec 31, 2021 | 7.94 Bn |
| Dec 31, 2021 | 7.94 Bn |
| Sep 30, 2020 | -26.00 Mn |
| Sep 30, 2020 | -26.00 Mn |
| Jun 30, 2020 | 4.45 Bn |
| Jun 30, 2020 | 4.45 Bn |
| Mar 31, 2019 | 4.96 Bn |
| Mar 31, 2019 | 4.96 Bn |
| Dec 31, 2016 | 1.07 Bn |
| Dec 31, 2016 | 1.07 Bn |
| Jun 30, 2016 | 8.00 Mn |
| Jun 30, 2016 | 8.00 Mn |
| Sep 30, 2015 | -2.00 Mn |
| Sep 30, 2015 | -2.00 Mn |
| Jun 30, 2015 | -1.00 Mn |
| Jun 30, 2015 | -1.00 Mn |
| Mar 31, 2015 | 7.94 Bn |
| Mar 31, 2015 | 7.94 Bn |
| Dec 31, 2014 | 3.15 Bn |
| Dec 31, 2014 | 3.15 Bn |
| Jun 30, 2014 | 1.00 Mn |
| Jun 30, 2014 | 1.00 Mn |
| Dec 31, 2012 | 58.00 Mn |
| Dec 31, 2012 | 58.00 Mn |
| Sep 30, 2012 | 2.50 Bn |
| Sep 30, 2012 | 2.50 Bn |
| Dec 31, 2010 | 1.99 Bn |
| Dec 31, 2010 | 1.99 Bn |